Langbahn Team – Weltmeisterschaft

JJC8-091

JJC8-091
Clinical data
Drug classAtypical dopamine reuptake inhibitor
Identifiers
  • 1-[4-[2-[bis(4-fluorophenyl)methylsulfinyl]ethyl]piperazin-1-yl]propan-2-ol
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC22H28F2N2O2S
Molar mass422.53 g·mol−1
3D model (JSmol)
  • CC(CN1CCN(CC1)CCS(=O)C(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)O
  • InChI=1S/C22H28F2N2O2S/c1-17(27)16-26-12-10-25(11-13-26)14-15-29(28)22(18-2-6-20(23)7-3-18)19-4-8-21(24)9-5-19/h2-9,17,22,27H,10-16H2,1H3
  • Key:PHGOEMMHIGVMIN-UHFFFAOYSA-N

JJC8-091 is an atypical dopamine reuptake inhibitor (DRI) that was derived from modafinil.[1][2][3][4] It is a lead compound for potential treatment of psychostimulant use disorder (PSUD) and is under development by Encepheal Therapeutics for use as a pharmaceutical drug.[5]

The affinity (Ki) of JJC8-091 for the dopamine transporter (DAT) is 230 to 289 nM.[5][1][6][7] In another study however, its affinities for the monoamine transporters were 16.7 nM for the DAT, 17,800 nM for the norepinephrine transporter (NET) (1,066-fold lower than for the DAT), and 1,770 nM for the serotonin transporter (SERT) (106-fold lower than for the DAT).[2] It has substantially higher affinity for the DAT than modafinil (Ki = 2,600–8,160 nM).[2][5] Besides the DAT, JJC8-091 is a sigma σ1 receptor ligand (Ki = 454–1,010 nM; 2.0–3.5-fold lower than for the DAT).[5][6][7][8] It also has high affinity for the dopamine D2 and D3 receptors and lower affinity for the dopamine D4 receptor (Ki = 298 nM, 480 nM, and 3,820 nM, respectively).[7]

JJC8-091 results in a mild, slow-onset, long-duration increase in dopamine levels in the nucleus accumbens in animals.[1][3] The increases in nucleus accumbens dopamine levels with JJC8-091 are blunted relative to those with cocaine and JJC8-088 (a cocaine-like DRI) but are greater than those of JJC8-016 (an atypical DRI).[4] JJC8-091 does not increase locomotor activity in animals, is not self-administered, and does not substitute for cocaine, suggesting very low addictive potential.[3][4][1] Additionally, it reduces cocaine and methamphetamine self-administration, decreases escalation of methamphetamine intake, and blocks cocaine-induced reinstatement of drug-seeking behaviors.[3][1][5][4] Unlike analogues including JJC8-088, JJC8-089, and RDS03-94, JJC8-091 did not show pro-motivational effects in animals.[9][10]

JJC8-091 was first described in the scientific literature by 2016.[7] It shows a favorable predicted drug-like profile in terms of metabolism and pharmacokinetics.[1][7] However, JJC8-091, similarly to analogues like JJC8-016, has been found to exert hERG inhibition.[11] In any case, modafinil and novel analogues like JJC8-091 are of interest in the potential treatment of PSUD.[12][1][5]

See also

References

  1. ^ a b c d e f g Jordan CJ, Cao J, Newman AH, Xi ZX (November 2019). "Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine". Neuropharmacology. 158: 107609. doi:10.1016/j.neuropharm.2019.04.015. PMC 6745247. PMID 31009632.
  2. ^ a b c Aggarwal S, Mortensen OV (2023). "Discovery and Development of Monoamine Transporter Ligands". Drug Development in Psychiatry. Advances in Neurobiology. Vol. 30. pp. 101–129. doi:10.1007/978-3-031-21054-9_4. ISBN 978-3-031-21053-2. PMC 10074400. PMID 36928847. {{cite book}}: |journal= ignored (help)
  3. ^ a b c d Hersey M, Bartole MK, Jones CS, Newman AH, Tanda G (July 2023). "Are There Prevalent Sex Differences in Psychostimulant Use Disorder? A Focus on the Potential Therapeutic Efficacy of Atypical Dopamine Uptake Inhibitors". Molecules. 28 (13): 5270. doi:10.3390/molecules28135270. PMC 10343811. PMID 37446929.
  4. ^ a b c d Tanda G, Hersey M, Hempel B, Xi ZX, Newman AH (February 2021). "Modafinil and its structural analogs as atypical dopamine uptake inhibitors and potential medications for psychostimulant use disorder". Curr Opin Pharmacol. 56: 13–21. doi:10.1016/j.coph.2020.07.007. PMC 8247144. PMID 32927246.
  5. ^ a b c d e f Newman AH, Ku T, Jordan CJ, Bonifazi A, Xi ZX (January 2021). "New Drugs, Old Targets: Tweaking the Dopamine System to Treat Psychostimulant Use Disorders". Annu Rev Pharmacol Toxicol. 61: 609–628. doi:10.1146/annurev-pharmtox-030220-124205. PMC 9341034. PMID 33411583.
  6. ^ a b Giancola JB, Bonifazi A, Cao J, Ku T, Haraczy AJ, Lam J, Rais R, Coggiano MA, Tanda G, Newman AH (December 2020). "Structure-activity relationships for a series of (Bis(4-fluorophenyl)methyl)sulfinylethyl-aminopiperidines and -piperidine amines at the dopamine transporter: Bioisosteric replacement of the piperazine improves metabolic stability". Eur J Med Chem. 208: 112674. doi:10.1016/j.ejmech.2020.112674. PMC 7680422. PMID 32947229.
  7. ^ a b c d e Cao J, Slack RD, Bakare OM, Burzynski C, Rais R, Slusher BS, Kopajtic T, Bonifazi A, Ellenberger MP, Yano H, He Y, Bi GH, Xi ZX, Loland CJ, Newman AH (December 2016). "Novel and High Affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues as Atypical Dopamine Transporter Inhibitors". J Med Chem. 59 (23): 10676–10691. doi:10.1021/acs.jmedchem.6b01373. PMC 5161041. PMID 27933960.
  8. ^ Hersey M, Mereu M, Jones CS, Bartole MK, Chen AY, Cao J, Hiranita T, Chun LE, Lopez JP, Katz JL, Newman AH, Tanda G (May 2024). "Dual DAT and sigma receptor inhibitors attenuate cocaine effects on nucleus accumbens dopamine dynamics in rats". Eur J Neurosci. 59 (10): 2436–2449. doi:10.1111/ejn.16293. PMC 11108740. PMID 38444104.
  9. ^ Meka, Nicolette M. "Assessment of Effort-related Motivational Effects of Novel Modafinil Analogs from NIDA Laboratories". ProQuest. Retrieved 22 September 2024.
  10. ^ Ecevitoglu A, Meka N, Rotolo RA, Edelstein GA, Srinath S, Beard KR, Carratala-Ros C, Presby RE, Cao J, Okorom A, Newman AH, Correa M, Salamone JD (July 2024). "Potential therapeutics for effort-related motivational dysfunction: assessing novel atypical dopamine transport inhibitors". Neuropsychopharmacology. 49 (8): 1309–1317. doi:10.1038/s41386-024-01826-1. PMC 11224370. PMID 38429498.
  11. ^ Ku TC, Cao J, Won SJ, Guo J, Camacho-Hernandez GA, Okorom AV, Salomon KW, Lee KH, Loland CJ, Duff HJ, Shi L, Newman AH (February 2024). "Series of (([1,1'-Biphenyl]-2-yl)methyl)sulfinylalkyl Alicyclic Amines as Novel and High Affinity Atypical Dopamine Transporter Inhibitors with Reduced hERG Activity". ACS Pharmacol Transl Sci. 7 (2): 515–532. doi:10.1021/acsptsci.3c00322. PMC 10863442. PMID 38357284.
  12. ^ Hersey M, Bacon AK, Bailey LG, Coggiano MA, Newman AH, Leggio L, Tanda G (2021). "Psychostimulant Use Disorder, an Unmet Therapeutic Goal: Can Modafinil Narrow the Gap?". Front Neurosci. 15: 656475. doi:10.3389/fnins.2021.656475. PMC 8187604. PMID 34121988.
Quelle: https://en.wikipedia.org/wiki/JJC8-091